# Michael B. Atkins

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-b-atkins/

## Facts

| Field | Value |
| --- | --- |
| Citations | 95,663 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 123 |
| i10-index | 464 |
| Last Known Institution | Georgetown University |
| OpenAlex ID | https://openalex.org/A5052526230 |
| ORCID iD | https://orcid.org/0000-0003-3901-9924 |
| Works | 1,068 |

## Researcher papers

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma](https://scholariq.org/papers/final-version-of-the-american-joint-committee-on-cancer-staging-system-for/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System](https://scholariq.org/papers/prognostic-factors-analysis-of-17-600-melanoma-patients-validation-of-the/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials](https://scholariq.org/papers/meta-analysis-of-phase-ii-cooperative-group-trials-in-metastatic-stage-iv/)
- [A new American Joint Committee on Cancer staging system for cutaneous melanoma](https://scholariq.org/papers/a-new-american-joint-committee-on-cancer-staging-system-for-cutaneous-melanoma/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [Georgetown University](https://scholariq.org/institutions/georgetown-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.